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Enabling Technologies for Cell-Based Clinical Translation
Concise Review: Organoids Are a Powerful Tool for
the Study of Liver Disease and Personalized
Treatment Design in Humans and Animals
SATHIDPAK NANTASANTI,a,b,c ALAIN DE BRUIN,b,d JAN ROTHUIZEN,a LOUIS C. PENNING,a
BAUKJE A. SCHOTANUSa
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ABSTRACT
Organoids are three-dimensional culture systems in which adult stem cells and their progeny grow
and represent thenativephysiologyof the cells in vivo.Organoidshavebeensuccessfully derived from
several organ systems in both animalmodels and human patients. Organoids have been used for fun-
damental research, diseasemodeling, drug testing, and transplantation. In this review,we summarize
the applications of liver-derived organoids and discuss their potential. It is likely that organoids will
provide an invaluable tool to unravel disease mechanisms, design novel (personalized) treatment
strategies, and generate autologous stem cells for gene editing and transplantation purposes.
STEM CELLS TRANSLATIONAL MEDICINE 2016;5:325–330
SIGNIFICANCE
Organoids derived from the liver have hepatocellular differentiation potential and can be an unlim-
ited source for hepatocytes for application in in vitro toxicology testing and for transplantation pur-
poses as an alternative to orthotopic liver transplantation. The in vitro representation of the native
physiology and epigenetic background of the adult liver stem cellsmakes the organoid technology an
excellent tool to study andmodel liver diseases, for drug screening, and for the design of personalized
treatments. This review summarizes the applications of liver organoids and discusses their potential
in the study and modeling of liver diseases, and in the development and testing of novel drugs.
INTRODUCTION
There has been increased interest in adult hepatic
stem/progenitor cells (HPCs) because they have
the potential to provide an unlimited source of
hepatocytes. Cell therapy may be an important
alternative to orthotopic liver transplantation
[1–3]. In addition, human hepatocytes are also
the gold standard for in vitro toxicology tests. Un-
fortunately, availability of mature hepatocytes is
limited because of their low replicative potential
in vitro [3], rapid dedifferentiation during culture
[4], and loss of viability and function following
cryopreservation [5]. Efficient generation of func-
tional hepatocytes or hepatocyte-like cells from
HPCs with unlimited expansion capacity in vitro
would enable effective stem cell-based therapies
and toxicology studies. In addition, it would boost
the research field by providing a valuable cell
source for fundamental research, disease model-
ing, drug screening, and personalized medicine.
HPCs are considered a good eligible source
for hepatocytes and hepatocyte-like cells, com-
paredwithembryonic stemcells (ESCs) or induced
pluripotent stem cells (iPSCs): HPC differentiation
is more efficient and less time consuming [6],
HPCs have lower risk for spontaneous mutations,
chromosomal rearrangements, and teratoma for-
mation [7], and they are less of a concern ethi-
cally. To harness the full potential of HPCs, a
robust method for the isolation and culture of
these cells from patients with liver disease is es-
sential. This review discusses the potential of
HPCs in the form of liver organoids and their
advantages and disadvantages. In particular,
we focus on the recently developed liver
organoid technology, and do not include three-
dimensional (3D) cocultures, which are also
often defined as liver organoids elsewhere in
the literature.
CULTURES OF HEPATIC STEM/PROGENITOR CELLS
There have been many attempts at isolating
HPCs for long-term culture. Traditionally, two-
dimensional (2D) culture of HPCs is relatively easy
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without loss of stem cell characteristics is difficult [8], and chro-
mosome alterations often occur with higher passages [9]. More-
over, cells grown in 2D conditions fail to recapitulate in vivo cell
polarization and cellular interactions, and poorly maintain in vivo
cell characteristics required for proper function. Finally, tissue-
specific architecture, mechanical and biochemical cues, and
cell-cell communication are absent under 2D conditions [10].
The development of 3D liver cell cultures partly circumvents
these issues, allowing hepatocyte polarization and interactions
between cells and theirmicroenvironment [4]. Recently, a 3D cul-
ture system of adult HPCs was developed with genetically stable,
long-term (.1 year) expansion. These cultureswerederived from
fluorescence-activated cell-sorted Lgr5+ (injuredmouse liver) and
EpCAM+ (normal human liver) ductal cells, and from biliary duct
fragments fromnormal and/or diseasedmurine and human livers
[11, 12]. The cultures were grown in laminin-rich Matrigel. Many
characteristics of the cells’ original epithelial architecture were
maintained, and the organoids were differentiated in vitro to-
ward hepatocytes and cholangiocytes. Upon transplantation into
injured mouse livers, the organoids gave rise to morphologically
and functionally mature hepatocytes [11, 12].
A great benefit of organoids is that they can be isolated from
patients by using less invasive Tru-cut needle biopsies or fine-
needle aspiration. Biopsied tissues are enzymatically digested
to retrieve biliary duct fragments that grow into organoids,
whereas fine-needle aspirates provide cells for direct culture,
resulting in organoid growth. We observed that tissues kept in
a cold medium for 2 days, frozen in dimethylsulfoxide-based
freezing medium or immediately snap-frozen in liquid nitrogen,
were suitable for liver organoid isolation.Moreover, the organoids
themselves canbecryopreservedand recovered,which is of critical
importance for cellbanking [11]. Together, thismeans that collecting
cells andsubsequentcultureoforganoids canbe fromvarious sources
and are not limited to highly invasive liver surgery. This recent devel-
opment of 3D liver cell culture is therefore very attractive for future
translational applications.
APPLICATIONS OF ORGANOIDS
Thepotential applications for andpros and consof liver organoids
are summarized in Figure 1 and Table 1, respectively.
Organoids for Fundamental Research
Organoids are currently considered one of the better platforms
for studying developmental questions regarding cell differentia-
tion and maturation. In particular, we can direct the differentia-
tion of liver organoids toward hepatocyte-like cells by Notch
inhibition and/or Wnt signaling [13]. Moreover, transcriptional
factors and regulatory pathways involved in organ specification
and late cell-fate determination can be investigated during
organoid development to gain a better understanding of disease
development and progression.
Organoids for Disease Modeling
Geneticmodification of HPCs to create disease-specific models in
vitro is of specific interest for rare diseases like Wilson disease,
especially when acquisition of patient material is challenging.
For example, human organoids derived from a1-antitrypsin defi-
ciency and patients with Alagille syndrome reflect the in vivo pa-
thologies of these diseases; apparently, these genetic defects did
not influenceorganoid proliferation [12]. This in vitro reflectionof
in vivo phenotype provides opportunities to investigate disease
mechanisms and develop new treatment strategies and, at
the same time, reduce experimental animal use. To date, liver
organoids are only used to model genetic liver diseases. In this
article, we discuss the potential use of liver organoids in other
research areas.
Liver Organoids to Study Viral Hepatitis
Hepatitis B virus (HBV) and hepatitis C virus (HCV) are hepato-
tropic viruses that affect more than 350 million people world-
wide. The ability to propagate these viruses in vitro is crucial to
obtain a detailed understanding of virus-host cell interaction
[14]. The lack of suitable cell cultures for HBV and HCV has ham-
pered the analysis of the viral life cycle and drug discovery. To
date, there is no in vitro experimental system for viruses that sup-
ports the entire viral life cycle, sustains high viral entry and rep-
lication, and permits patient-derived viral isolates [14, 15].
Primary human hepatocyte cultures represent the most physio-
logically relevant system and are highly susceptibile to HBV and
HCV infection [16, 17]. However, their limited availability, short
life span in culture, and low viral replication in hepatocytes be-
cause of hepatic interferon-g production have impeded the use
of this model [18, 19]. The human hepatoma cell line Huh7.5 is
currently the most widely used cell system because these cells
can sustain high HCV titers. A significant drawback of Huh7.5 cells
is lack of polarity and, therefore, nonproductive infection of
patient-derived isolates [15]. A recent report described the first
human hepatoma cell line, HLCZ01, that permits direct HBV
and HCV infection by patient sera [18]. In addition to hepato-
cellular cell lines and primary hepatocytes, stem cell-derived
hepatocyte-like cells have gained interest. Several studies have
demonstrated that iPSC- and/or ESC-derivedhepatocyte-like cells
can be infected with HCV [15].
Despite availability of these in vitro models, there are still
some issues that cannot be addressed simultaneously with the
current models (e.g., host-virus interaction [20], the budding-
off processof infectiousparticles). HPCshavebeenshownsuscep-
tible to HCV infection and, unlike pluripotent stem cells and
definitive endoderm, are able to bud-off infectious particles
[19, 21]. Based on these arguments, organoids could be an excel-
lent model for the study of viral hepatitis. It is expected that
hepatocyte-likecellsdifferentiated frompatient-derivedorganoids
could overcome the current limitations for several reasons.
First, organoids retain their innate immune response. Second,
the 3D structure of differentiated liver organoids allows for cor-
rect cell polarization, facilitating HBV and HCV cell entry and cell-
to-cell transmission. Third, the possibility of performing genetic
modification in long-term organoid cultures holds great promise
for generating virus-resistant hepatocyte-like cells for potential
life-saving therapy. Thus, organoidsmay provide an excellent cul-
ture system to study and to model viral hepatitis.
Liver Organoids to StudyNonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) has a 91% prevalence in
obese patients, with an astonishingly high incidence in children.
NAFLD is amultifacetedandcomplicateddisease characterizedby
steatosis. Patients with NAFLDmay develop nonalcoholic steato-
hepatitis (NASH),whichmayprogress to cirrhosis and, eventually,
cancer. Generally, NAFLD is caused by interactions between
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environmental and genetic factors; however, the precise patho-
genesis and transition to NASH are not clearly understood
[22–24]. This warrants the development of experimental models
that mimic the human condition. Previous studies using primary
hepatocyte cultures, immortalized cell lines, cocultures of hepa-
tocytes with adipocytes, and precision-cut slices of perfused liver
have confirmed several pathways involved in NAFLD-to-NASH
progression, both in vitro (human) and in vivo (animal models)
[23]. Unfortunately, animal experimental models, although ad-
vantageous in defining cause-and-effect relationships, do not
fully recapitulate humanNAFLD/NASHwith respect to the degree
of hepatocellular damageandmetabolic alterations [23]. Purehe-
patocyte cultures enable investigation into genetic stability and/
or fatmetabolismduring NAFLD/NASH transition. Fibrosis, on the
other hand, is a complex interplay between various cell types and
obviously requires more complex coculture systems [25]. In this
respect, liver organoid-derived hepatocyte-like cells may be ad-
vantageous. Because the genetic signature of a patient is main-
tained and cultures are stable in the long term, the influence of
genetic background and hepatocellular pathways of NAFLD/
NASH becomes testable. In addition, epigenetic alterations im-
portant in the development and progression of NAFLD [24] can
be specifically studied in patient-derived organoids. Elucidation
of epigenetic factors may identify early diagnostic biomarkers
and therapeutic strategies for NAFLD.
A more comprehensive approach to investigating the inter-
cellular mechanisms of NAFLD and progression to NASH includes
coculture of organoids with other cell types (e.g., stellate cells,
Kupffer cells, other inflammatory cells). In addition, tissue
engineering and 3D printing technologies provide further oppor-
tunities tomimic the complex liver in vitro. Finally, organoid tech-
nology has been established for several species, including human,
mouse, and dog [13];most recently, we have succeeded in cultur-
ing organoids from various cat livers. Taken together, we are now
inapositionwhere technologies can complement relevant animal
models, and parallel investigations into various species with dif-
ferent disease susceptibilities only strengthen our translational
approaches.
Organoids for Personalized Medicine
The clinical potential of patient-derived organoids has been re-
ported for patients suffering from cystic fibrosis, which is caused
by a mutation in the CFTR gene. CFTR function was efficiently re-
stored in organoids (intestinal, colon, and pulmonary) derived
from these patients, either by chemical compounds or by the
CRISPR-Cas9 genome editing strategy [26–28]. This allowed pre-
clinical ex vivo testing of new CFTR-targeted drugs to customize
treatments for individual patients or to target specific CFTR mu-
tations (precision therapy) [29, 30]. It is conceivable that this ap-
proach may be similarly effective for liver organoids.
Liver Organoids and Hepatocellular Carcinoma
Human hepatocellular carcinoma (HCC) is associated with a high
prevalence of chromosome copy-number alterations and translo-
cations, as well as somatic mutations. The genetic heterogeneity,
even within the same pathological tumor classification, affects
clinical features, clinical care, and prognosis of the individual
Figure 1. Application for liver organoids in regenerative medicine and cancer. The scheme represents the potential of liver organoids for fun-
damental research and translation to the clinic. Organoids are isolated and cultured from human and animal patients. Organoids can be ge-
netically modified for cancer research and rare diseases. Gene correction can be performed ex vivo in patient-specific organoids before
autologous transplantation. Upon differentiation, organoids may be used for multiple purposes, including disease modeling, drug testing, tox-
icology, and transplantation, that are essential for development of personalized and precision therapies.
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patient [31]. It has been demonstrated that pancreatic organoids
generated from neoplastic murine and human pancreas tissues
[32], upon transplantation, recapitulate the pathophysiology of
pancreatic tumor development. Transcriptional and proteomic
analyses identified expression of the same genes and pathways
in these organoids and their original human tissues [32]. Similar re-
sults were obtained in organoids derived from colorectal carci-
noma [33]. In our laboratory, we were able to culture organoids
from liver tumors and normal tissues simultaneously from the
samepatient, providing theopportunity toperformdeep sequenc-
ing analysis to identifymutations and altered signaling pathways in
individual tumors. We anticipate that testing specific anticancer
drugs in patient-derived tumor organoids will consequently pro-
vide predictive data on patient-specific treatment efficacy.
Organoids for Transplantation
Liver organoids are attractive for transplantation, because of
their potential to be substitutes for primary hepatocytes, which,
themselves, demonstrate excellent posttransplant repopulation
capacity. Liver organoids expand rapidly; allow autologous
transplantation, thus avoiding immunoreaction; and are geneti-
cally stable. Upon transplantation in mice, neither dysplastic
nor anaplastic growth was found in any of the organoid-
transplanted recipient mice [11, 12, 34]. This contrasts with iPSCs,
which are known to have an unpredictable degree of differentia-
tion and a higher risk for teratoma formation [7, 35]. These char-
acteristics strongly indicate that organoid transplantationmay be
a safer counterpart to iPSC-based strategies. To fully rescue met-
abolic or genetic defects, adequate engraftment efficiency of
transplanted cells is necessary. Currently, only 1% engraftment
of organoids has been reported [11], whereas at least 10% en-
graftment is required to restore enzyme or protein deficiency
[3, 36]. Strategies such as priming the recipient livermay improve
organoid engraftment. A tremendous ethical and logistical advan-
tage of liver organoids is that they can be grown from liver biopsy
specimens taken from living donors or patients by relatively min-
imally invasive techniques. Because gene manipulation can be
performed in patient-derived organoids ex vivo, the corrected
organoids can be selectively expanded to reach desired numbers
for autologous transplantation.
ORGANOIDS IN ANIMALS
Canine and Feline Liver Progenitor Cultures
There ismuch need for new regenerative treatment strategies for
veterinary patients. This is especially true for companion animals,
where the standard of care approaches the level of human clinical
care. Many liver diseases in dogs and cats develop in the same
manner as observed in human patients [37, 38]. It is, therefore,
conceivable that organoid generation from these species may ac-
celerate the translational benefit in human medicine, with the
added advantage of fewer ethical and administrative obstacles.
Several canine adult HPC culture systems have been available
since the early 1990s—for example, the canine bile duct epithelial
cell line, established from gall bladder epithelial cells [39]; a hepa-
tocellular tumor cell line, which was derived from a clinical/
spontaneous HCC in a dog [40]; and a primary nonparenchymal cell
fraction enriched with small hepatocytes and small epithelial cells
fromnormal,maturedog livers [38].Despite this, apureHPCculture
systemwith long-term, genetically stable culture potential was not
achieveduntil recently. Toour knowledge, thereare still noHPCcul-
ture systems available for felines. Our recently established canine
and feline liver organoids may provide an alternative for the devel-
opment of transplantation therapy, investigation of disease mech-
anisms, and development of personalized treatment strategies.
Liver Organoids to Study Canine and Feline Liver
Diseases and Cancers
Hepatitis is one of the most common liver diseases in dogs. Be-
cause the etiology is most often unknown, therapeutic strategies
rely on symptoms and histopathological descriptions [41]. Canine
hepatitis andhuman viral hepatitis sharemany characteristics, in-
cluding similar molecular pathways, histopathological lesions,
clinical signs, and disease progression [37]. It is generally thought,
Table 1. Pros and cons of liver organoid technology
Application Pros Cons
Fundamental research Studies in Studies in cell biology of fully mature hepatocytes or cholangiocytes,
because of the low differentiation potential.• Stem cell biology
• Cell-cell interaction
• Cell-ECM interaction studies
(in coculture)
Disease modeling • Cell banking possibility Disease models with fully mature epithelial cells will require improved




• Patient-specific cell culture
systems
Selective procedures for corrected clones are needed.
• Potential for genome editing
Drug screening and toxicology • Suitable for long-term
testing
Mature hepatocytes require improved differentiation methods.
Transplantation • No risk for teratoma • Low differentiation potential
• Potential for gene correction
and autologous
transplantation
• New protein expression upon gene correction requiring
immunosuppression
Abbreviation: ECM, extracellular matrix.
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therefore, that canine hepatitis, like human hepatitis, is viral in
origin; however, its identity and nature remain elusive [41]. Ca-
nine liver organoids could provide us with a tool for testing hepa-
tocellular infectivity and viral propagation to develop targeted
treatment strategies.
The most common form of liver disease in cats is hepatic lip-
idosis, for which obese animals are at higher risk [42] and which
resembles human NAFLD. Because cats are considered an excel-
lentmodel for the study ofmetabolic diseases in humans [43], fe-
line liver organoids enable us to better understand individual
differences in susceptibility and to identify cellular andmolecular
mechanisms of feline and human hepatic lipid-storage diseases.
Another common liver disease in cats is lymphocytic cholangitis, a
classificationofhepatobiliary disease [44]. Thisdiseasehas similar
histological features asprimary sclerosing cholangitis andprimary
biliary cirrhosis (PBC) in humans; however, the etiology and path-
ogenesisof thesediseases arenot clearlydefined [45]. Liverorganoids
derived from biliary duct fragments of feline patients could be
an effective tool for in vitro analysis of primary biliary function
andmorphology [13], aswell asdrug screening.Moreover, organoids
with a bipotential differentiation capacity may be able to renew at
least some of the defective biliary trees in patients, providing
an alternative for liver transplantation. An established model
of primary sclerosing cholangitis/PBC for feline cholangitis could
lead tonovel combination therapies,which, in turn,may facilitate
new drug development for human clinical practice.
Finally, cancermay soonbecome the leading causeof death in
companion animals, as a result of increased life span. It has been
observed that the same cancer types often develop in both hu-
mans and companion animals [46]. The development of novel
treatment strategies and personalized treatments for tumors in
pets, using organoid technology, will, therefore, mutually benefit
the human and veterinary fields.
CHALLENGES OF USING LIVER ORGANOIDS
Liver organoids are available for several species and open newav-
enues for liver therapeutics [11–13]. Rodents remain important
models for fundamental studies; dogs andcats serve toaccelerate
preclinical translationalmodels at low cost; andhuman organoids
are of incredible value for the analysis of patient-specific disease
mechanisms and treatment efficacy. Because of similarities in dis-
ease development, canine HPC transplantation may provide a
bridge from fundamental findings to the human clinic.
Although full hepatic differentiation is not critical for transplan-
tation purposes [11, 12], it is essential to improve the in vitro effi-
ciency of hepatic differentiation for disease modeling and
preclinical pharmatoxicological studies. This may be achieved
throughadaptationofmedia compositionandculture components.
For example, recapitulation of the in vivoextracellularmatrix (ECM)
remains challenging. It has been demonstrated that the use of
decellularized liver ECM improvesprimary hepatocyte culture func-
tion [47], andwesuggest this couldhavesimilareffectsonorganoid-
derived hepatocyte-like cells. Further development of coculture
organoid systems, along with improving spatial architecture (e.g.,
3D printing), may enable more efficient hepatic differentiation.
Generating effective 3D liver organoids, however, is not with-
out its own challenges. First, it is laborious and expensive. Second,
organoids are cultured in a matrix environment, requiring alterna-
tive approaches to sample handing, manipulation, and functional
assays. Finally, to analyze intact 3D structures, novel imaging
and quantitative analysis techniquesmust be implemented. Fortu-
nately, these techniques are evolving concurrently with organoid
technology, and published transfection, transduction [48], high-
throughput screening [33], and3D imagingandanalysis techniques
[13] demonstrate that this convergence of tools will facilitate the
powerful application of organoids for regenerative strategies.
CONCLUSION
To date, 3D organoid technology is the best available representa-
tion of the in vivo physiology of native epithelial liver cells. Organoid
cultures have greatly enhanced our underlying knowledge of
disease development and progression, have demonstrated faith-
ful recapitulation of disease pathways in vivo, and are currently
available froma variety of species. These elements, togetherwith
emerging technologies (such as 3D printing and imaging tech-
niques), and the abundanceof opportunities in research, drugdis-
covery, and patient-specific applications, indicate that organoids
may significantly contribute to the changing landscapeof howdis-
eases are studied and medicine developed.
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